## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|---|
| Applicant(s) | : | Toshiyuki Takai, et al. |
| U.S. Appln. No. | : | 10/712,118 |
| U.S. Filing Date | : | November 13, 2003 |
| Title of Invention | : | NON-HUMAN ANIMAL MODEL OF OLIGODENDROCYTE DEVELOPMENTAL DISORDER |
| Confirm No. | : | 8301 |
| Examiner | : | Joanne Hama, Ph.D |
| Art Unit | : | 1632 |

745 Fifth Avenue
New York, NY 10151

**FILED VIA *EFS-WEB***
**MAY 9, 2008**

## REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

**ON THE FACE OF THE PATENT**

(75)    Toshiyuki Takai, "Sendai" --Miyagi-- (JP)

**IN THE CLAIMS**

Col. 19, claim 2, line 28

The transgenic mouse model of claim 1, wherein the homozygous disruption in the DAP12 gene can be "pheonotypically" --phenotypically-- exhibited as a myelinogenesis developmental disorder.

Col. 20, claim 5, lines 25 and 27

The transgenic mouse model of claim 1, "weherein" --wherein-- the expression of myelin basic protein in the brain is weak in regions where DAP "space" 12 is strongly expressed in wild-type mice.

## REMARKS

The requested changes do not constitute new matter and this application does not require re-examination. A completed Form PTO 1050 is enclosed. In the correction to claim 5, line 27, Applicant is requesting that the Office delete the space between "DAP" and "12." Therefore, the compound should read as "DAP12."

Since the errors to be corrected are the Applicants' errors, the Commissioner is authorized to charge any fee occasioned by this paper to Deposit Account No. 50-0320. The Commissioner is also authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP


By: _Deborah L. Lu_

Thomas J. Kowalski
Reg. No. 32,147

Deborah L. Lu
Reg. No. 50,940
Telephone: (212) 588-0800
Facsimile: (212) 588-0500

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

Page 1 of 1

| | | |
|---|---|---|
| PATENT NO. | : | 7,332,644 |
| APPLICATION NO. | : | 10/712,118 |
| ISSUE DATE | : | February 19, 2008 |
| INVENTOR(S) | : | Toshiyuki Takai |
| | | Hiroaki Aso |
| | | Michihiro Fujiwara |

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

## ON THE FACE OF THE PATENT

(75)        Toshiyuki Takai, "Sendai" --Miyagi-- (JP)

## IN THE CLAIMS

Col. 19, claim 2, line 28

The transgenic mouse model of claim 1, wherein the homozygous disruption in the DAP12 gene can be "pheonotypically" --phenotypically-- exhibited as a myelinogenesis developmental disorder.

Col. 20, claim 5, line 25 and 27

The transgenic mouse model of claim 1, "weherein" ---wherein-- the expression of myelin basic protein in the brain is weak in regions where DAP " "12 is strongly expressed in wild-type mice.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Thomas J. Kowalski, Esq.
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, New York 10151

00546524